CC
TLSI icon

Centiva Capital’s TriSalus Life Sciences TLSI Stock Holding History

Centiva Capital’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-66,711
Closed -$662K – 1624
2022
Q3 		$662K Hold
66,711
– – 0.01% 781
2022
Q2 		$656K Buy
66,711
+13,347
+25% +$131K 0.02% 814
2022
Q1 		$523K Buy
+53,364
New +$527K 0.01% 955

Other funds holding TLSI

MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.55B AUM 23.63% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Centiva Capital's TLSI Position: Q4 2022 in Review

Centiva Capital sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 66,711 shares — an estimated $662K sold.

Centiva Capital first reported a position in TLSI in Q1 2022 and held it in 3 quarters. The position peaked at $662K in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Centiva Capital reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Centiva Capital sold 66,711 TriSalus Life Sciences shares in Q4 2022, an estimated $662K.
  • Centiva Capital first reported a position in TriSalus Life Sciences in Q1 2022 and held it in 3 quarters.
  • Centiva Capital's TriSalus Life Sciences position peaked at $662K in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Centiva Capital's 13F filing for Q4 2022, filed 14 Feb 2023.